Trial record 5 of 9 for:
NIS793
FOLFIRINOX + NIS793 in Pancreatic Cancer
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT05417386 |
|
Recruitment Status :
Recruiting
First Posted : June 14, 2022
Last Update Posted : August 23, 2022
|
Sponsor:
Colin D. Weekes, M.D.
Collaborator:
Novartis
Information provided by (Responsible Party):
Colin D. Weekes, M.D., Massachusetts General Hospital
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Brief Summary:
This research is being done to evaluate the safety and effectiveness of the drug NIS793 in combination with the standard of care treatment FOLFIRINOX (consists of the drugs 5-Fluorouracil (5-FU), Oxaliplatin, Irinotecan, and Leucovorin), chemoradiation and surgery for people with metastatic pancreas adenocarcinoma.
The drugs involved in this study are:
- NIS793
- FOLFIRINOX (consists of the drugs 5-Fluorouracil (5-FU), Oxaliplatin, Irinotecan, and Leucovorin)
Other interventions include
- chemoradiation
- surgery.
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| Pancreas Cancer Metastatic Pancreatic Cancer Metastatic Pancreatic Adenocarcinoma | Drug: FOLFIRINOX Drug: Oxaliplatin Drug: Leucovorin Drug: Irinotecan Drug: 5-Fluorouracil (5-FU) Drug: NIS793 Radiation: Chemoradiation Drug: Capecitabine Radiation: Radiation Therapy Procedure: Surgery | Phase 1 |
This is a two part Phase 1B study investigating whether NIS793 improves the clinical benefit of FOLFIRINOX treatment for metastatic pancreas adenocarcinoma.The first part is a safety run-in using a dose escalation strategy to determine the recommended phase 2 dose of the drug NIS793. In the second part participants will be a randomized assigned to receive either FOLFIRINOX plus NIS793 or FOLFIRINOX alone.
NIS793 binds to the protein that can be found on tumor cells, called TGFβ, thereby preventing its role in cancer metastasis (spreading). FOLFIRINOX is a combination of 4 chemotherapy drugs that may help shrink tumors.
The U.S. Food and Drug Administration (FDA) has not approved NIS793 as a treatment for any disease.
The FDA has approved FOLFIRINOX as a treatment option for metastatic pancreas adenocarcinoma The FDA has not approved the combination of NIS793 and FOLFIRINOX as a treatment for any disease.
The research study procedures include screening for eligibility and study treatment including evaluations and follow up visits.
It is expected that about 50 people will take part in this research study.
Novartis, a pharmaceutical company, is supporting this research study by providing funding for the study, including the study drug.
| Study Type : | Interventional (Clinical Trial) |
| Estimated Enrollment : | 50 participants |
| Allocation: | Randomized |
| Intervention Model: | Parallel Assignment |
| Masking: | None (Open Label) |
| Primary Purpose: | Treatment |
| Official Title: | A Phase IB Study FOLFIRINOX and NIS793 in Patients With Pancreatic Cancer |
| Actual Study Start Date : | August 9, 2022 |
| Estimated Primary Completion Date : | December 1, 2024 |
| Estimated Study Completion Date : | May 1, 2025 |
Resource links provided by the National Library of Medicine
MedlinePlus related topics:
Pancreatic Cancer
| Arm | Intervention/treatment |
|---|---|
|
Experimental: Safety Run-In
Following a 3 + 3 dose escalation design 6-18 participants will receive NIS793 and FOLFIRINOX on day 1 of each 14 day cycle for 3+ cycles until recommended phase 2 dose is determined.
|
Drug: FOLFIRINOX
Combination of the drugs 5-Fluorouracil (5-FU), Oxaliplatin, Irinotecan, and Leucovorin given by intravenous infusion Drug: NIS793 Given by intravenous infusion |
|
Experimental: FOLFIRINOX
Participants will be randomly assigned to receive:
|
Drug: FOLFIRINOX
Combination of the drugs 5-Fluorouracil (5-FU), Oxaliplatin, Irinotecan, and Leucovorin given by intravenous infusion Drug: Oxaliplatin Part of the FOLFIRINOX drug combination, given by intravenous infusion
Other Name: Eloxatin Drug: Leucovorin Part of the FOLFIRINOX drug combination, given by intravenous infusion
Other Names:
Drug: Irinotecan Part of the FOLFIRINOX drug combination, given by intravenous infusion
Other Names:
Drug: 5-Fluorouracil (5-FU) Part of the FOLFIRINOX drug combination, given by intravenous infusion
Other Name: Adrucil Radiation: Chemoradiation Combination of Chemo (Capecitabine) and Radiation Therapy Drug: Capecitabine Taken Orally as part of Chemoradiation
Other Name: Xeloda Radiation: Radiation Therapy Radiation Therapy as part of Chemoradiation Procedure: Surgery Surgical removal of tumor |
|
Experimental: FOLFIRINOX + NIS793
Participants will be randomly assigned to receive:
|
Drug: FOLFIRINOX
Combination of the drugs 5-Fluorouracil (5-FU), Oxaliplatin, Irinotecan, and Leucovorin given by intravenous infusion Drug: Oxaliplatin Part of the FOLFIRINOX drug combination, given by intravenous infusion
Other Name: Eloxatin Drug: Leucovorin Part of the FOLFIRINOX drug combination, given by intravenous infusion
Other Names:
Drug: Irinotecan Part of the FOLFIRINOX drug combination, given by intravenous infusion
Other Names:
Drug: 5-Fluorouracil (5-FU) Part of the FOLFIRINOX drug combination, given by intravenous infusion
Other Name: Adrucil Drug: NIS793 Given by intravenous infusion Radiation: Chemoradiation Combination of Chemo (Capecitabine) and Radiation Therapy Drug: Capecitabine Taken Orally as part of Chemoradiation
Other Name: Xeloda Radiation: Radiation Therapy Radiation Therapy as part of Chemoradiation Procedure: Surgery Surgical removal of tumor |
Primary Outcome Measures :
- Safety Run In-Recommended Phase 2 dose (RP2D) [ Time Frame: Up to 2 months after baseline ]Primary endpoint of safety run-in cohort is to define the recommended phase 2 dose as analyzed by 2-dimensional imaging (Computed Tomography, CT) or MRI utilizing Response Evaluation Criteria in Solid Tumors (RECIST v.1.1), obtained at 4-cycle therapy intervals.
- R0 Resection Rate [ Time Frame: Up to 8 months after baseline ]The primary endpoint of the two-arm non-comparative phase IB study (Part 2) is to estimate the R0 resection rate associated with the FOLFIRINOX/NIS793 therapy administered as neoadjuvant therapy.
Secondary Outcome Measures :
- Disease-Free Survival (DFS) [ Time Frame: Up to approximately 6 years after baseline ]Defined as the time from time of surgical resection of pancreas tumor to the earlier of progression or death due to any cause. Participants alive without disease progression are censored at date of last disease evaluation.
- Progression-free survival (PFS) [ Time Frame: Up to approximately 6 years after baseline ]
Defined from the date of randomization or registration to the earliest date of progressive disease or death due to any cause. Progressive disease must be documented objectively in one or more local and/or distant sites. PFS will be censored at the date of last follow-up for patients alive without documented progression.
PFS curves will be estimated by the Kaplan-Meier method and compared using the logrank test.
- Overall survival (OS) [ Time Frame: Up to approximately 6 years after baseline ]Defined as date of randomization or registration to the date of death due to any cause and censored at the date of last follow-up for patients still alive. OS curves will be estimated by the Kaplan-Meier method and compared using the log-rank test.
- Pathologic complete response (pCR) [ Time Frame: up to 8 months after baseline ]Defined as no residual cancer in the pancreatic tissue at surgical resection. The pCR rate will be reported among all eligible patients as well as among resected patients with 95% confidence intervals based on the exact binomial distribution. Comparisons between arms may be assessed using Fisher's exact test.
- Resection rate [ Time Frame: up to 8 months after baseline ]Percentage of patient who undergo resection of their primary tumor, regardless of microscopic location of residual tumor to location of the resection margin.
Information from the National Library of Medicine
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria:
- Safety Run-in Cohort: Histologically confirmed metastatic pancreatic adenocarcinoma without prior therapy for pancreatic adenocarcinoma.
- Phase 1B Cohort: Histologically confirmed locally advanced disease (borderline resectable or locally advanced pancreatic adenocarcinoma) or poorly differentiated adenosquamous carcinoma includes both borderline resectable or locally advanced disease. Patients with localized pancreas adenocarcinoma cannot have received any prior therapy for borderline resectable or locally advanced pancreas adenocarcinoma
- Borderline Resectable Disease: Defined by the NCCN as tumors with venous involvement of the SMV/portal vein demonstrated tumor abutment with or without impingement and narrowing of the lumen, either tumor thrombus or encasement but with suitable vessel proximal and distal to the area of vessel involvement, allowing for safe resection or reconstruction; gastroduodenal artery encasement up to the hepatic artery with either short segment encasement or direct abutment of the hepatic artery, without extension to the celiac axis; or tumor abutment of the SMA not to exceed greater than 180 degrees of the circumference of the vessel wall.Tumors involving retroperitoneal structures that can be surgically removed (i.e.kidney), will also be included.
- Locally Advanced Pancreas Adenocarcinoma: Defined by the NCCN as: Tumors of the head that have greater than 180 degrees of SMA encasement or any celiac abutment, unreconstructable SMV or portal occlusion, or aortic invasion or encasement. Tumors of the body with SMA or celiac encasement of greater than 180 degrees, unreconstructable SMV or portal occlusion, or aortic invasion. Tumors of the tail with SMA or celiac encasement of greater than 180 degrees. Irrespective of location, all tumors with evidence of nodal metastasis outside of the resection field are deemed unresectable. Participants must have measurable disease, defined as at least one lesion that measured in at least one dimension (longest diameter to be recorded for non-nodal lesions and short axis for nodal lesions) as ≥20 mm (≥2 cm) by chest x-ray or as ≥10 mm (≥1 cm) with CT scan, MRI, or calipers by clinical exam. See Section 12 (Measurement of Effect) for the evaluation of measurable disease.
- Age ≥18 years.
- ECOG performance status ≤2 (Karnofsky ≥60%, see Appendix A).
-
Participants must have adequate organ and marrow function as defined below:
- Absolute neutrophil count ≥1,500/mcL
- Platelets ≥100,000/mcL
- Total bilirubin ≤ 1.5 institutional upper limit of normal (ULN) if no biliary stenting has been done OR 2.0 x ULN if patient is status post biliary stenting or two downward trending values.
- AST(SGOT)/ALT(SGPT) Safety Run-in Metastatic Disease: < 5 x institutional ULN. Locally advanced disease: ≤3 × institutional ULN
- Creatinine ≤ institutional ULN OR
-
Glomerular filtration rate (GFR) no lower than 60 mL/min/1.73 m2
- Creatinine clearance for males = (140 - age [yrs]) (body wt [kg]) / (72) (serum creatinine [mg/dL])
- Creatinine clearance for females = 0.85 x male value
- Human immunodeficiency virus (HIV)-infected participants on effective antiretroviral therapy with undetectable viral load within 6 months are eligible for this trial.
- For participants with evidence of chronic hepatitis B virus (HBV) infection, the HBV viral load must be undetectable on suppressive therapy, if indicated.
- Participants with a history of hepatitis C virus (HCV) infection must have been treated and cured. For participants with HCV infection who are currently on treatment, they are eligible if they have an undetectable HCV viral load.
- Participants with treated brain metastases are eligible if follow-up brain imaging after central nervous system (CNS)-directed therapy shows no evidence of progression. Additionally, participants with new or progressive brain metastases (active brain metastases) or leptomeningeal disease are eligible if the treating physician determines that immediate CNS specific treatment is not required and is unlikely to be required during the first cycle of therapy.
- Participants with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen are eligible for this trial.
- Participants with known history or current symptoms of cardiac disease, or history of treatment with cardiotoxic agents, should have a clinical risk assessment of cardiac function using the New York Heart Association Functional Classification.
To be eligible for this trial, participants should be class. To be eligible for study participation, participants must be class 2 B or better.
- The effects of treatment on the developing human fetus are unknown. For this reason, all patients of child-bearing potential must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation and 9 months after completion of mFOLFIRINOX or NIS793 administration. Should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately.
- Ability to understand and the willingness to sign a written informed consent document.
Exclusion Criteria:
- Metastatic Disease Safety Run-in: Any prior chemotherapy, radiation therapy, immunotherapy, biologic ('targeted') therapy or investigational therapy for pancreas adenocarcinoma.
- Locally Advanced Disease Cohort: Any prior chemotherapy, radiation therapy, immunotherapy, biologic ('targeted') therapy or investigational therapy for treatment of the patient's pancreatic tumor.
- Major surgery, excluding laparoscopy, within 4 weeks of the start of study treatment, without complete recovery
- Patients with deficient mismatch/microsatellite unstable or high tumor mutation burden cancers.
- Participation in any investigational drug study within 4 weeks preceding the start of study treatment.
- Participants who have not recovered from adverse events due to prior anti-cancer therapy (i.e., have residual toxicities > Grade 1) with the exception of alopecia.
- Patients requiring use of steroids to treat active uncontrolled brain metastases will be excluded from study enrollment. Patients treated with radiation > 4 weeks prior with follow up imaging showing control are eligible.
- History of allergic reactions attributed to compounds of similar chemical or biologic composition to NIS793, 5-fluorouracil, irinotecan and oxaliplatin not amenable to institutional chemotherapy desensitization protocol.
- Known, existing uncontrolled coagulopathy. Concomitant treatment with full dose warfarin (coumadin) is NOT allowed. Patients may receive low molecular weight heparin (LMWH) (such as enoxaparin and dalteparin) and direct oral anticoagulant (DOAC) for management of deep venous thrombosis (DVT).
- History of bleeding diathesis or recent major bleeding events (i.e. Grade > 2 bleeding events in the month prior to treatment).
- Concomitant use of cimetidine, as it can decrease clearance of 5FU. Another H2- blocker or proton pump inhibitor may be substituted before study entry.
- Patient with cardiac ventricular arrhythmias requiring antiarrhythmic therapy, or atrioventricular heart block (due to 5FU administration)
- Participants with uncontrolled intercurrent illness or infection.
- Participants with uncontrolled seizures, central nervous system disorders or psychiatric illness/social situations that would limit compliance with study requirements.
- Has received a live vaccine within 30 days of planned start of study therapy. Note:
Seasonal influenza vaccines for injection are generally inactivated flu vaccines and are allowed; however intranasal influenza vaccines (e.g., Flu-Mist®) are live attenuated vaccines, and are not allowed. COVID non-live vaccines are allowed.
- History of severe hypersensitivity reaction to any monoclonal antibody.
- Patient with known history of UGT1A1 gene polymorphism, Patient with known history of UGT1A1 gene polymorphism.
Information from the National Library of Medicine
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT05417386
Contacts
| Contact: Colin D Weekes, MD, PhD | 617-724-8700 | cdweekes@mgh.harvard.edu | |
| Contact: Joanna L Caufield, RN | 617-724-8735 | jlcaufield@partners.org |
Locations
| United States, Massachusetts | |
| Massachusetts General Hospital Cancer Center | Recruiting |
| Boston, Massachusetts, United States, 02114 | |
| Contact: Colin D Weekes, MD PhD 617-724-8700 cdweekes@mgh.harvard.edu | |
| Principal Investigator: Colin D Weekes, MD PhD | |
Sponsors and Collaborators
Colin D. Weekes, M.D.
Novartis
Investigators
| Principal Investigator: | Colin D Weekes, MD, PHD | Massachusetts General Hospital |
| Responsible Party: | Colin D. Weekes, M.D., Principal Investigator, Massachusetts General Hospital |
| ClinicalTrials.gov Identifier: | NCT05417386 |
| Other Study ID Numbers: |
22-082 |
| First Posted: | June 14, 2022 Key Record Dates |
| Last Update Posted: | August 23, 2022 |
| Last Verified: | August 2022 |
| Individual Participant Data (IPD) Sharing Statement: | |
| Plan to Share IPD: | Yes |
| Plan Description: | The Dana-Farber / Harvard Cancer Center encourages and supports the responsible and ethical sharing of data from clinical trials. De-identified participant data from the final research dataset used in the published manuscript may only be shared under the terms of a Data Use Agreement. Requests may be directed to: [contact information for Sponsor Investigator or designee]. The protocol and statistical analysis plan will be made available on Clinicaltrials.gov only as required by federal regulation or as a condition of awards and agreements supporting the research. |
| Supporting Materials: |
Study Protocol Statistical Analysis Plan (SAP) Informed Consent Form (ICF) |
| Time Frame: | Data can be shared no earlier than 1 year following the date of publication |
| Access Criteria: | Contact the Partners Innovations team at http://www.partners.org/innovation |
| Studies a U.S. FDA-regulated Drug Product: | Yes |
| Studies a U.S. FDA-regulated Device Product: | No |
Keywords provided by Colin D. Weekes, M.D., Massachusetts General Hospital:
|
Pancreas Cancer Metastatic Pancreatic Cancer Metastatic Pancreatic Adenocarcinoma |
Additional relevant MeSH terms:
|
Adenocarcinoma Pancreatic Neoplasms Carcinoma Neoplasms, Glandular and Epithelial Neoplasms by Histologic Type Neoplasms Digestive System Neoplasms Neoplasms by Site Endocrine Gland Neoplasms Digestive System Diseases Pancreatic Diseases Endocrine System Diseases Leucovorin Capecitabine Fluorouracil |
Oxaliplatin Irinotecan Folfirinox Camptothecin Levoleucovorin Physiological Effects of Drugs Antimetabolites, Antineoplastic Antimetabolites Molecular Mechanisms of Pharmacological Action Antineoplastic Agents Immunosuppressive Agents Immunologic Factors Topoisomerase I Inhibitors Topoisomerase Inhibitors Enzyme Inhibitors |